Anthrax AV7909 Boost Evaluation Study
Public ClinicalTrials.gov record NCT05997264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blinded, Multicenter Study in Healthy Adults to Evaluate Safety and Immunogenicity of AV7909 Administered at Two Dose Levels on Two Vaccination Schedules, Including a Primary Series and Booster Doses
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, phase 2, double-blinded, multicenter study is designed to assess the safety and immune response kinetics of CYFENDUS™ (henceforth AV7909) administered on 2 primary series vaccination schedules followed by 6- and 12-month boosters.
Study identification
- NCT ID
- NCT05997264
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Interventions
- AV7909 Full Dose (0.5 mL) Biological
- AV7909 Half Dose (0.25 mL) Biological
- Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) Biological
- Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 4, 2023
- Primary completion
- Aug 27, 2025
- Completion
- Jul 31, 2026
- Last update posted
- Feb 23, 2026
2023 – 2026
United States locations
- U.S. sites
- 7
- U.S. states
- 2
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Accellacare of Hickory | Hickory | North Carolina | 28601 | — |
| Accellacare of Salisbury | Salisbury | North Carolina | 28144 | — |
| Accellacare of Piedmont | Statesville | North Carolina | 28625 | — |
| Accellacare of Winston-Salem | Winston-Salem | North Carolina | 27103 | — |
| Accellacare Knoxville | Jefferson City | Tennessee | 37760 | — |
| Accellacare Knoxville | Knoxville | Tennessee | 37912 | — |
| Accellacare Knoxville | Knoxville | Tennessee | 37938 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05997264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05997264 live on ClinicalTrials.gov.